Century Therapeutics (IPSC) Accumulated Expenses (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Accumulated Expenses of $8.5 million for Q1 2026, up 187.94% year-over-year from $2.9 million in Q1 2025, and down 27.4% quarter-over-quarter from $11.7 million in Q4 2025.
Century Therapeutics (IPSC) Accumulated Expenses (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Accumulated Expenses for 7 consecutive years, with $8.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 187.94% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (up 187.94% YoY), while the FY2025 annual figure was $11.7 million, down 33.13% from the prior year.
- Accumulated Expenses fell to $8.5 million in Q1 2026 per IPSC's latest filing, from $11.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $17.5 million in Q4 2024 and bottomed at $721000.0 in Q3 2022.
- Historically, Accumulated Expenses has averaged $7.9 million across 5 years, with a median of $7.2 million in 2022.
- Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 90.07% — and 2023, when it soared 1277.53%.
- Century Therapeutics' Accumulated Expenses stood at $7.1 million in 2022, then declined by 8.01% to $6.5 million in 2023, then jumped by 168.8% to $17.5 million in 2024, then slumped by 33.13% to $11.7 million in 2025, then slipped by 27.4% to $8.5 million in 2026.
- Business Quant data shows IPSC's Accumulated Expenses at $8.5 million in Q1 2026, $11.7 million in Q4 2025, and $11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.25 Mn |
| Mar 31, 2026 | 8.48 Mn |
| Dec 31, 2025 | 11.68 Mn |
| Sep 30, 2025 | 11.05 Mn |
| Jun 30, 2025 | 11.72 Mn |
| Mar 31, 2025 | 2.94 Mn |
| Dec 31, 2024 | 17.46 Mn |
| Sep 30, 2024 | 6.22 Mn |
| Jun 30, 2024 | 11.10 Mn |
| Mar 31, 2024 | 2.87 Mn |
| Dec 31, 2023 | 6.50 Mn |
| Sep 30, 2023 | 9.93 Mn |
| Jun 30, 2023 | 7.86 Mn |
| Mar 31, 2023 | 6.53 Mn |
| Dec 31, 2022 | 7.06 Mn |
| Sep 30, 2022 | 721,000.00 |
| Jun 30, 2022 | 7.25 Mn |
| Mar 31, 2022 | 4.85 Mn |
| Dec 31, 2021 | 6.04 Mn |
| Sep 30, 2021 | 7.26 Mn |